Foxy 5 - CAS 881188-51-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C26H42N6O12S2
Molecular Weight:
694.77
COA:
Inquire
Targets:
Wnt
Description:
Foxy 5 is a Wnt signaling pathway modulator used for the treatment of metastatic breast cancer, prostate cancer and colorectal cancer. It impairs migration and invasion of 4T1 breast cancer cells in vitro.
Brife Description:
Wnt signaling pathway modulator
Synonyms:
Foxy-5; Foxy 5; Foxy5
MSDS:
Inquire
InChIKey:
WFZPJYYCTSHDJI-ATIWLJMLSA-N
InChI:
InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)/t14-,15-,16-,17-,18-/m0/s1
Canonical SMILES:
CC(C)CC(C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CS)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CCSC)NC=O
1.Migration and invasion of oral squamous carcinoma cells is promoted by WNT5A, a regulator of cancer progression.
Prgomet Z;Axelsson L;Lindberg P;Andersson T J Oral Pathol Med. 2015 Nov;44(10):776-84. doi: 10.1111/jop.12292. Epub 2014 Dec 2.
BACKGROUND: ;Oral squamous cell carcinoma (OSCC) constitutes 90% of all cancers in the oral cavity, and the prognosis for patients diagnosed with OSCC is still poor. The identification of novel therapeutic targets and prognostic markers for OSCC is therefore essential. Previous studies of OSCC revealed an increased expression of WNT5A in the tumor tissue. However, no functional studies of WNT5A-induced effects in OSCC have been performed.;METHODS: ;Two different OSCC cell lines were used for analysis of WNT5A expression by Western blot, whereas WNT5A-induced responses were analyzed by measuring calcium (Ca²⁺) signaling, PKC activation, migration and invasion.;RESULTS: ;Despite the lack of WNT5A expression, both cell lines responded to recombinant WNT5A (rWNT5A) with activation of the non-canonical WNT/Ca²⁺ /PKC pathway. This effect was ascertained to be mediated by WNT5A by use of the WNT5A antagonist, Box5. To investigate how WNT5A affects tumor progression, rWNT5A-induced alterations in BrdU absorbance (reflecting the number of tumor cells) were analyzed. rWNT5A had no effect on BrdU absorbance but instead promoted tumor cell migration and invasion. These results were confirmed by the use of the WNT5A-mimicking peptide Foxy5, while the rWNT5A-induced migration was blocked by secreted Frizzled-related protein 1 (SFRP1), protein kinase C inhibitors or the intracellular Ca²⁺ chelator, MAPT.
2.RETRACTED ARTICLE
Ford CE;Ekström EJ;Howlin J;Andersson T Cell Cycle. 2009 Jun 15;8(12):1838-42. Epub 2009 Jun 27.
Despite improvements in detection and treatment, breast cancer remains the most common female cancer worldwide, and metastatic associated mortality is a significant public health issue. Patients with tumors negative for estrogen receptor (ERalpha), have a particularly poor prognosis, partly due to their inability to respond to current endocrine treaments. Expression of Wnt-5a has been associated with prolonged recurrence free survivial in clinical material, and Wnt-5a also inhibits migration and invasion of breast cancer cell lines. Loss of Wnt-5a is associated with loss of ERalpha in clinical breast cancer material, and Wnt-5a signaling upregulates ERalpha in ERalpha negative breast cancer cell lines. A Wnt-5a derived hexapeptide, Foxy-5, has been developed and like Wnt-5a, increases adhesion and inhibits migration of breast cancer cells. Furthermore, Foxy-5 significantly reduced liver and lung metastases in a murine ERalpha negative breast cancer model. Foxy-5 also upregulated ERalpha in this in vivo model and most significantly, in vitro rendered cells responsive to the selective estrogen receptor modulator, Tamoxifen. Together these studies suggest that Foxy-5 may be a potential new supplementary treatment for ERalpha negative breast cancer patients, as it addresses two of the most important aspects of cancer related mortality -- non response to endocrine therapy and metastasis.
3.RETRACTED ARTICLE
Ford CE;Ekström EJ;Andersson T Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3919-24. doi: 10.1073/pnas.0809516106. Epub 2009 Feb 23.
One third of all breast cancers are estrogen receptor alpha (ERalpha) negative, carry a poor overall prognosis, and do not respond well to currently available endocrine therapies. New treatment strategies are therefore required. Loss of Wnt-5a has previously been correlated with loss of ERalpha in clinical breast cancer samples, and we sought to investigate this association further. Three breast cancer cell lines (MDA-MB-231, MDA-MB-468, and 4T1) lacking expression of ERalpha and Wnt-5a, and one breast cancer cell line (T47D) expressing both proteins were used in this study. Wnt-5a signaling was generated in ERalpha-negative cell lines via stimulation with either recombinant Wnt-5a protein or a Wnt-5a-derived hexapeptide (Foxy-5) possessing Wnt-5a signaling properties. ERalpha expression was restored at both mRNA and protein level, after treatment with recombinant Wnt-5a or Foxy-5. This restoration of expression occurred in parallel with a reduction in methylation of the ERalpha promoter. Up-regulated ERalpha could be activated, initiate transcription of progesterone receptor and pS2, and activate an estrogen response element reporter construct. Significantly, breast cancer cells re-expressing ERalpha responded to treatment with the selective estrogen receptor modulator tamoxifen, as measured by induction of apoptosis and cell growth inhibition.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Wnt Products


CAS 909089-13-0 SKL 2001

SKL 2001
(CAS: 909089-13-0)

SKL 2001 is a Wnt/β-catenin signaling pathway agonist that modulates the differentiation of mesenchumal stem cells. It upregulates the β-catenin responsive tran...

CAS 292168-79-7 KY1220

KY1220
(CAS: 292168-79-7)

KY1220 is a novel inhibitor of the Wnt/ß-catenin pathway, destabilizing both β-catenin and Ras via targeting the Wnt/β-catenin pathway (IC50= 2.1 μM in HEK293 r...

CAS 1127442-87-8 exo-IWR 1

exo-IWR 1
(CAS: 1127442-87-8)

exo-IWR 1, the enantiomer of IWR-1 and the diastereomer of IWR-1-endo, is a potent SAR anticancer Wnt response inhibitor, which is a kind of small secreted prot...

CAS 664969-54-4 LF3

LF3
(CAS: 664969-54-4)

LF3 is a potent inhibitor of Wnt/β-catenin signaling (IC50= 1.65 μM), but does not interfere with E-cadherin/β-catenin-mediated cell-cell adhesion.antitumor act...

CAS 1467013-03-3 Adavivint

Adavivint
(CAS: 1467013-03-3)

Adavivint is a Wnt pathway inhibitor.

CAS 9050-30-0 Heparan Sulfate

Heparan Sulfate
(CAS: 9050-30-0)

Heparan sulfate, a complex and linear polysaccharide in which the backbone is composed of repeating sulfated disaccharide units, exists as part of glycoproteins...

WAY 262611 dihydrochloride

WAY 262611 dihydrochloride is an inhibitor of Dickkopf-1 (DKK1), which antagonizes Wnt/β-Catenin signaling. DKK1 is a soluble inhibitor of Wnt-3a mediated Wnt/β...

CAS 1127442-82-3 IWR-1-endo

IWR-1-endo
(CAS: 1127442-82-3)

IWR-1-endo is a potent inhibitor of the Wnt response, blocking a cell-based Wnt/β-catenin pathway reporter response with an IC50 value of 180 nM.

Chemical Structure

CAS 881188-51-8 Foxy 5

Quick Inquiry

Verification code

Featured Items